Insilico reported first-half revenue and profit
Insilico Medicine’s interim report for the six months ended June 30, 2026 recorded revenue of $106.303 million, compared with $27.456 million in the prior-year period. The same report listed profit for the period of $35.537 million, compared with a $19.215 million loss a year earlier.
The report also listed adjusted non-IFRS profit of $51.227 million. That adjusted measure is separate from both revenue and reported profit. The interim financial information was unaudited, although the report says the company’s independent auditor reviewed it.
The business connects a platform with drug programs
The company describes itself as an AI-driven drug discovery and development business. Its interim report discusses a generative AI platform, drug discovery and pipeline development, research collaborations, and licensing activity as parts of the commercial model.
The report said drug discovery and pipeline development generated $103.1 million in revenue during the first half of 2026. That business-line figure is included within, and should not be added on top of, the company’s $106.303 million total revenue.
Recursion’s 2025 revenue came with a net loss
Recursion reported $74.7 million in total revenue for 2025, compared with $58.8 million in 2024. Fourth-quarter revenue was $35.5 million, and the company said total revenue consisted primarily of collaboration agreements.
The company also reported a $644.8 million net loss for 2025, compared with a $463.7 million loss in 2024. The revenue and loss describe separate lines of the financial results; the annual revenue figure is not profit.
Sources and reporting boundaries
Sources: Insilico Medicine, Interim Report 2026, covering the six months ended June 30, 2026; Recursion, fourth-quarter and full-year 2025 financial results. The interim report’s financial information is unaudited and auditor-reviewed. Recursion’s figures are company-reported results.
Public materials do not state that Insilico or Recursion used APIToken（https://apitoken.company/）. APIToken（https://apitoken.company/） provides a unified compatible model interface, public model status, usage records, and budget controls; current availability follows the live site.